Mara Goldstein
Stock Analyst at Mizuho
(2.39)
# 2,518
Out of 5,124 analysts
70
Total ratings
45.28%
Success rate
11.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $410 → $600 | $21.01 | +2,755.78% | 2 | Jan 27, 2026 | |
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $7.83 | +283.14% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.53 | +295.26% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $6.67 | +19.94% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $21.03 | +99.71% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $11.61 | +330.66% | 2 | Jan 22, 2024 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $108.39 | -28.96% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $12.29 | -43.04% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.14 | +601.75% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $36.81 | +144.50% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $20.46 | -82.89% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.99 | +17,990.45% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $4.93 | +305.68% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $121.93 | +6.62% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $5.67 | -64.73% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.42 | +745.07% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $62.34 | -67.92% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $11.86 | +304.72% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $23.83 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $7.32 | +91.26% | 1 | Oct 12, 2017 |
Syndax Pharmaceuticals
Jan 27, 2026
Maintains: Outperform
Price Target: $410 → $600
Current: $21.01
Upside: +2,755.78%
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $7.83
Upside: +283.14%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.53
Upside: +295.26%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.67
Upside: +19.94%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $21.03
Upside: +99.71%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $11.61
Upside: +330.66%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $108.39
Upside: -28.96%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $12.29
Upside: -43.04%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.14
Upside: +601.75%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $36.81
Upside: +144.50%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $20.46
Upside: -82.89%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.99
Upside: +17,990.45%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $4.93
Upside: +305.68%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $121.93
Upside: +6.62%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $5.67
Upside: -64.73%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.42
Upside: +745.07%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $62.34
Upside: -67.92%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $11.86
Upside: +304.72%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $23.83
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $7.32
Upside: +91.26%